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with DFI are Medicare-eligible, and hospitals are motivated to
decrease costs without altering patient outcomes. A large, mul-
ticenter, randomized, double-blind trial (SIDESTEP) comparing
ertapenem (1g QD) and piperacillin/tazobactam (3.375g QID)
found equivalent efﬁcacy in the treatment of DFI. METHODS:
Individuals enrolled in SIDESTEP, treated entirely as inpatients,
and clinically evaluable at ﬁnal assessment (10 days after com-
pleting antibiotic therapy; n = 99) were included. Cost per dose
was calculated from a) average actual hospital acquisition
price/dose (IMS Health, National Sales Perspectives) for 2005 in
U.S. dollars for ertapenem ($40.52) or piperacillin/tazobactam
($13.58); b) average U.S. wage and beneﬁts for labor, based a
review of 10 time-and-motion studies of intravenous antibiotic
drug preparation and administration ($3.03); and c) consumable
supplies, using a 40% discount off manufacturer list price in the
2005 Redbook ($2.52). For each patient, actual doses (either
ertapenem or piperacillin/tazobactam) was multiplied by total
cost per dose (ertapenem = $45.23; piperacillin/tazobactam =
$19.13). RESULTS: No differences with respect to demograph-
ics, mean length of treatment or wound severity were 
noted (intravenous therapy days: ertapenem = 6.6; piperacillin/
tazobactam = 6.4); (wound severity: ertapenem = 29%;
piperacillin/tazobactam = 26% severe). Differences were signiﬁ-
cant with respect to mean doses of active drug (ertapenem = 7.6;
piperacillin/tazobactam = 25.7; p < 0.0001) and costs (ertapenem
= $352.11; piperacillin/tazobactam = $491.20; p = 0.018). The
$139.10 difference between groups accounts for approximately
3% of total hospital DRG reimbursements for Medicare
patients. CONCLUSIONS: Once-daily dosing of ertapenem
offers the advantage of less cost to hospitals, compared to QID
dosing for piperacillin/tazobactam, without compromising 
efﬁcacy or safety.
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OBJECTIVES: Ribavirin-induced anemia is a common adverse
effect of chronic hepatitis C treatment. Pilot studies have shown
that the use of epoetin has decreased the need for ribavirin dose
reduction or discontinuation. Our goal was to calculate the
incremental cost-effectiveness of using epoetin to treat ribavirin-
induced anemia, per ribavirin dose reduction or discontinuation
averted. Our secondary aim was to calculate the incremental cost
of hepatitis C treatment, comparing those who developed anemia
to those who did not, using each of two strategies: ribavirin dose
reduction/discontinuation or epoetin. METHODS: Using esti-
mates from the literature and decision-analytic techniques, we
modeled treatment patterns and estimated the cost of managing
ribavirin-induced anemia. One-way sensitivity analyses were
used to address uncertainty. RESULTS: Clinically signiﬁcant
anemia, deﬁned as a 2 g/dL or greater reduction in hemoglobin,
developed in approximately 72% of patients in observational
studies. The cost-effectiveness of using epoetin to treat ribavirin-
induced anemia ranged from $39,579 (severe anemia, genotype-
2/3) to $52,200 (moderate anemia, genotype-1), per ribavirin
dose reduction/discontinuation averted. The incremental cost of
treating hepatitis C, comparing patients with anemia to those
without, using ribavirin dose reduction/discontinuation saved
$2742 (genotype-1) and $323 (genotype-2/3); when using
epoetin; the additional cost was $2075 and $5501, for genotype-
1 and genotype-2/3 patients, respectively. CONCLUSIONS: The
incremental cost of treating ribavirin—induced anemia is
minimal, and varies with the probability of developing anemia.
However, once anemia has developed, the cost of using epoetin
per ribavirin dose modiﬁcation averted is substantial; and varies
with the probability of response to epoetin. These ﬁndings
suggest that additional studies are warranted that will deﬁne
both genotype-speciﬁc strategies to treat ribavirin-induced
anemia and the optimal use of epoeitin as adjunctive therapy in
patients with chronic hepatitis C.
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OBJECTIVES: Military recruits undergo screening for LTBI at
accession with TST. The low speciﬁcity of TST results in false
positives and unnecessary LTBI treatment. A highly speciﬁc
whole blood assay for the diagnosis of LTBI exists (QFT—GIT,
Cellestis) pending FDA approval. Unlike TST, administration of
QFT-GIT at application to military service is feasible and would
permit exclusion of LTBI positives. We investigated the potential
cost savings of implementing universal application QFT-GIT
testing with or without conﬁrmatory accession QFT-GIT testing
and treatment, to determine whether QFT-GIT testing costs are
offset by reduced LTBI treatment costs. METHODS: A decision
tree was constructed to model the direct costs of TST testing and
LTBI treatment of accessions versus the costs of alternative poli-
cies of QFT-GIT applicant testing with or without conﬁrmatory
accession QFT-GIT testing and treatment. Average LTBI treat-
ment costs per positive test were expressed as a ratio to the cost
of QFT-GIT testing (treatment: cost ratio). Costs of administer-
ing and reading a TST were assumed to be zero, and QFT-GIT
costs were normalized per accession. RESULTS: Applicant QFT-
GIT testing was economical over TST above a treatment: cost
ratio of 52 :1, while conﬁrmatory QFT-GIT testing was eco-
nomical over TST above a treatment:cost ratio of 108 :1. In 
two-way sensitivity analysis, threshold ratios decreased with
increasing LTBI prevalence and increasing probability of acces-
sion and were relatively insensitive to uncertainty in test char-
acteristics. CONCLUSIONS: Application QFT-GIT results in
fewer LTBI positive accessions and should be implemented if
cost-beneﬁcial. Quantiﬁcation of the direct costs of LTBI treat-
ment are needed to determine the maximum cost of QFT-GIT
testing to economically implement this policy, and whether
improved sensitivity can be economically achieved with conﬁr-
matory QFT-GIT testing.
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OBJECTIVES: Streptococcus pneumoniae is a leading bacterial
cause of septicaemia, meningitis, pneumonia and otitis media
and may cause severe sequelae or death. A 7-valent conjugate
pneumococcal vaccine (Prevenar) has proved effective in pre-
venting otitis and invasive pneumococcal disease (IPD) in chil-
dren. A reduction in IPD has also been observed in some adult
age groups, possibly due to herd immunity. The aim of this study
was to explore the cost-effectiveness of vaccination of infants in
Norway. METHODS: The study was based on a Markov-model
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using data on the risk of pneumococcal disease, the serotype-
adjusted vaccine efﬁcacy, the vaccine price, decrease in the fre-
quency of adverse outcomes and quality of life for patients with
sequelae from pneumococcal disease. Due to uncertainty with
respect to herd immunity, results are presented both with and
without potential effects of herd immunity. RESULTS: Disre-
garding indirect costs, the incremental cost per QALY using 4
Prevenar doses was €96000 when herd immunity was included
and €140,000 when it was not (€57,000 and €83,000 if 3 doses
offer the same effectiveness as 4). Also accounting for indirect
costs, the numbers with 4 doses would be €37,000 and €56,000,
respectively. With the most optimistic assumptions, vaccination
would be cost saving. The vaccine price and efﬁcacy, and otitis
incidence were crucial factors in sensitivity analyses. Monte
Carlo simulations indicate that the results were robust to uncer-
tainty in other parameters. CONCLUSION: The cost-effective-
ness of pneumococcal vaccination will in particular depend on
the price of the vaccine, the efﬁcacy of the vaccine, the efﬁcacy
of three versus four vaccine shots, and the extent of herd immu-
nity. In Norway, €62,500 per QALY is the ofﬁcial cost-effec-
tiveness threshold. Vaccination can therefore be considered
cost-effective. In November 2005 the Norwegian Government
included Prevenar in the public vaccination program.
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OBJECTIVE: Invasive mycoses are associated with high mortal-
ity, therefore consuming important health care resources. Cost-
effectiveness of voriconazole vs. amphotericin B deoxycholate
(CAB) for the primary treatment of invasive aspergillosis (IA)
was evaluated using data from a randomized comparative trial
(Herbrecht, NEJM 2002), that showed the superiority of
voriconazole in terms of clinical response, survival and safety
when used as primary therapy for IA. METHODS: A model for
analytical decision was designed based on the information pro-
vided by this clinical study. Changes in the antifungal treatment
due to lack of response, as well as renal or hepatic toxicity with
the initial treatment were assessed, considering direct medical
costs only, reported in Argentine pesos. RESULTS: Average total
treatment cost in the voriconazole arm was $44,040 vs. $45,428
in the CAB arm. Using the model assumptions (efﬁcacy: 52.8%
for voriconazole, 31.6% for CAB) voriconazole was the domi-
nant treatment vs. CAB as primary therapy, with a cost per 
successfully treated patient of $83,444.96 vs. $143,858.26
respectively. One-way sensitivity analysis was performed in order
to assess the impact of relevant key variables (cost of antifun-
gals, cost of hospitalization, etc.) Even after changing these vari-
ables in a wide range, voriconazole was still cost-saving.
CONCLUSIONS: Incremental cost-effectiveness analysis indi-
cated that voriconazole was the dominant therapy due to both
lower costs and higher efﬁcacy.
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OBJECTIVES: Linezolid, the ﬁrst available oxazolidinone, has
shown efﬁcacy in the treatment of methicillin-resistant Staphy-
lococcus aureus (MRSA) infections, including nosocomial pneu-
monia. In patients with MRSA nosocomial pneumonia, survival
rate was higher for those treated with linezolid than patients
treated with vancomycin (80% versus 63.5%). Moreover, clini-
cal cure rate was superior for linezolid (59% vs 35.5%) (Chest
2003;124:1789–97). We analyzed the economic impact of these
clinical outcomes in an Argentinean setting using a decision-
analytic model. METHODS: A decision-analytic model was
developed to estimate the costs and consequences of using line-
zolid versus vancomycin in hospitalized patients with nosoco-
mial pneumonia in an Argentinean setting. Clinical and other
parameters were taken from published trials. Three Argentinean
infectologists provided data on resource utilization. For costing
purposes (tests, hospitalization, adverse events and drugs) ALFA-
BETA and IECS unit costs database were used (both are pub-
lished). Outcomes consisted of total costs per patient, cost per
death avoided, cost per life-year gained, and cost per cure.
RESULTS: According to the model results, an additional 14.3%
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